{"id":"NCT01355497","sponsor":"GTx","briefTitle":"Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum","officialTitle":"Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-07","primaryCompletion":"2013-05","completion":"2014-06","firstPosted":"2011-05-18","resultsPosted":"2020-11-09","lastUpdate":"2020-11-09"},"enrollment":330,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Muscle Wasting","Non-Small Cell Lung Cancer"],"interventions":[{"type":"DRUG","name":"GTx-024","otherNames":["enobosarm, ostarine"]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"GTx-024 3mg once daily","type":"EXPERIMENTAL"},{"label":"placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine if the investigational drug GTx-024 can help patients with non small cell lung cancer increase physical function and maintain or gain muscle.","primaryOutcome":{"measure":"Physical Function","timeFrame":"Day 84","effectByArm":[{"arm":"GTx-024","deltaMin":19.5,"sd":null},{"arm":"Placebo","deltaMin":24.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"30 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":13,"exclusionCount":11},"locations":{"siteCount":30,"countries":["United States"]},"refs":{"pmids":["27138015"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":109,"n":165},"commonTop":["Anemia","Nausea","Neutropenia","Vomiting","Thrombocytopenia"]}}